Get started
Author

Masaru Baba

Establishment and characteristics of a gastric cancer cell line (HuGC‐OOHIRA) producing high levels of G‐CSF, GM‐CSF, and IL‐6: The presence of autocrine growth control by G‐CSF
1995 · Masaru Baba, Hiroshi Hasegawa, et al. · American Journal of Hematology · 81
Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection
2020 · for the NORTE Study Group, Kazuharu Suzuki, et al. · Journal of Gastroenterology · 70
Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas
2002 · Hisaki Nagai, Yong Sung Kim, et al. · Cancer Letters · 57
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria
2020 · Takuya Sho, Goki Suda, et al. · Hepatology Research · 45
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting
2019 · Takuya Sho, Goki Suda, et al. · JGH Open · 45
PDF
Entecavir treatment of hepatitis B virus‐infected patients with severe renal impairment and those on hemodialysis
2019 · Kazuharu Suzuki, Goki Suda, et al. · Hepatology Research · 43
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
2021 · Takuya Sho, Goki Suda, et al. · Hepatology Research · 36
Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis
2020 · Koji Ogawa, Takashi Kobayashi, et al. · Scientific Reports · 31
PDF
Inactivation of SSI-1, a JAK/STAT inhibitor, in human hepatocellular carcinomas, as revealed by two-dimensional electrophoresis
2001 · Hisaki Nagai, Yong Sung Kim, et al. · Journal of Hepatology · 31
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
2022 · Shunichi Hosoda, Goki Suda, et al. · Liver Cancer · 26
PDF
Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection
2019 · for the NORTE Study Group, Goki Suda, et al. · Journal of Gastroenterology · 26
Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication
2022 · Masato Nakai, Yoshiya Yamamoto, et al. · Scientific Reports · 24
PDF
Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter
2019 · Takaaki Izumi, Takuya Sho, et al. · Hepatology Research · 22
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection
2018 · Goki Suda, Masayuki Kurosaki, et al. · Journal of Gastroenterology · 22
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis
2023 · Goki Suda, Masaru Baba, et al. · Journal of Medical Virology · 21
Discrimination of individuals in a general population at high-risk for alcoholic and non-alcoholic fatty liver disease based on liver stiffness: a cross section study
2011 · Masaru Baba, Ken Furuya, et al. · BMC Gastroenterology · 21
PDF
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment
2024 · Takuya Sho, Goki Suda, et al. · Targeted Oncology · 20
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
2022 · Takuya Sho, Goki Suda, et al. · Cancers · 18
PDF
Characterization of liver-cirrhosis nodules by analysis of gene-expression profiles and patterns of allelic loss
2004 · Hisaki Nagai, Yoshie Terada, et al. · Journal of Human Genetics · 14
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC
2025 · Risako Kohya, Goki Suda, et al. · JHEP Reports · 10
PDF
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2025 · Masatsugu Ohara, Goki Suda, et al. · Hepatology International · 9
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study
2024 · Zijian Yang, Goki Suda, et al. · Hepatology Research · 9
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma
2021 · Taku Shigesawa, Goki Suda, et al. · PLoS ONE · 9
PDF
Detection of genetic alterations in the human gastric cancer cell lines by two-dimensional analysis of genomic DNA.
2000 · Y S Kim, H S Yoo, et al. · International Journal of Oncology · 9
Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up
2024 · Yuji Ogawa, Wataru Tomeno, et al. · Hepatology Research · 8
PDF
Works count: 57
Citation count: 779
H-index: 18
I10-index: 20
Year
Topic
Type